AAN 2023
Psychiatry Congress Events
Apr 22-27
Boston, Massachusetts
The Risk of Depression in a Large Huntington Disease Population Compared With Controls: Analysis of the Enroll-HD Registry Data
Authors:
Shoshana Reshef, Gerald Smith, Ofir Harari, Mark Forrest Gordon, Rinat Ribalov, Sam Leo, Rosa Willock, José Robles-Zurita, Erin Furr Stimming, Victor Sung
Chorea Severity Change Over Time in Huntington Disease and by Huntington Disease Stage
Authors:
Erin Furr Stimming, Victor Sung, Shoshana Reshef, Rosa Willock, Rinat Ribalov, Sarah Brighton, Sam Leo
Baseline Characteristics and Treatment Patterns of a Global Huntington Disease Population Stratified by Chorea Severity
Authors:
Victor Sung, Erin Furr Stimming, Shoshana Reshef, Rosa Willock, Rinat Ribalov, Sarah Brighton, Sam Leo
Real-World Effectiveness and Safety of Deutetrabenazine in Combination with Antipsychotic Drugs in Patients With Chorea Associated With Huntington Disease
Authors:
Daniel Claassen, Hela Romdhani, Rajeev Ayyagari, Debbie Goldschmidt, Sarah Zoye Moroz, Adreanna Hernandez, Nayla Chaijale, Sam Leo
A bioequivalence comparison at steady state between the newly developed once-daily extended release tablet formulation and the approved twice daily tablet formulation of deutetrabenazine
Authors:
Eva-Maria Sunzel, Laura Rabinovich-Guilatt, Malini Iyengar, Debra Ruffo, Maria Gutierrez, Mark Forrest Gordon and Giulia Ghibellini
Assessment of dose proportionality of three dose strengths (6 mg, 12 mg and 24 mg) over the clinical dose range (6-48 mg) of the newly developed once daily extended release tablet formulation of deutetrabenazine
Authors:
Eva-Maria Sunzel, Giulia Ghibellini, Malini Iyengar, Maria Gutierrez, Debra Ruffo, Mark Gordon and Laura Rabinovich-Guilatt
This site is intended for US Healthcare Professionals only
NPS-US-NP-01222 | February 2024